mYOSITIS

Comparative, Double-Blind, Investigational Study Evaluating the Efficacy and Safety of Abatacept SC with Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults with Active Idiopathic Inflammatory Myopathy (IIM)

You Must:

Be diagnosed of definite or probable IIM

Demonstrate muscle weakness

Have active disease despite adequate prior treatment experience with corticosteroids, immunosuppressants, or biologic medications

You Must Not:

Have Inclusion Body Myositis or myositis other than IIM

Have been treated with rituximab in the past year or any other biologic treatment or IVIG in the past 6 months

This is a 52 week long investigational study – Visits occur at Screening, Baseline, and about every 4 weeks afterwards